期刊文献+

防治动脉粥样硬化的实验性疫苗研究进展 被引量:1

原文传递
导出
摘要 动脉粥样硬化(AS)是缺血性心脑血管疾病的最重要病理学基础。近年来,以降脂为核心的控制危险因素的治疗大大降低并延缓了As的发生,但却未能完全阻断其进展,As性疾病在未来数年内仍然是发病率和死亡率最高的疾病。
出处 《中华心血管病杂志》 CAS CSCD 北大核心 2012年第5期442-445,共4页 Chinese Journal of Cardiology
  • 相关文献

参考文献38

  • 1Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol, 2006,6:508-519.
  • 2Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med, 2005,352 : 1685-1695.
  • 3姚康,葛均波,孙爱军,洪晓武,施鸿毓,黄榕翀,贾庆哲,王克强,钟翠平,曹雪涛,邹云增.高糖对人单核细胞源树突状细胞分化成熟和免疫功能的影响及其机制研究[J].中华心血管病杂志,2006,34(1):60-64. 被引量:18
  • 4Gurfinkel E, Lernoud V. The role of infection and immunity in atherosclerosis. Expert Rev Cardiovasc Ther, 2006,4 : 131-137. Stassen FR, Vainas T, Bruggeman CA. Infection and atherosclerosis. An alternative view on an outdated hypothesis. Pharmacol Rep,2008 ,60 :85-92.
  • 5Stassen FR, Vainas T, Bruggeman CA. Infection and atherosclerosis. An ahemative view on an outdated hypothesis. Pharmacol Rep ,2005,60:85-92.
  • 6Shaw PX, Horkko S, Chang MK, et al. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J Clin Invest, 2000,105 : 1731-1740.
  • 7Tsimikas S, Brilakis ES, Lennon RJ, et al. Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events. J Lipid Res, 2007,48:425-433.
  • 8Palinski W, Miller E, Witztum JL. Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc Natl Acad Sci U S A, 1995, 92:821-825.
  • 9Freigang S, Horkko S, Miller E, et al. Immunization of LDL receptor-deficient mice with homologous malondialdehyde-modified and native LDL reduces progression of atheroselerosis by mechanisms other than induction of high titers of antibodies to oxidative neoepitopes. Arterioseler Thromb Vase Biol, 1998,18 : 1972-1982.
  • 10Zhou X, Caligiuri G, Hamsten A, et al. LDL immunizationinduces t-cell-dependent antibody formation and protection against atherosclerosis. Arterioscler Thromb Vasc Biol, 2001,21 : 108- 114.

二级参考文献12

  • 1贾庆哲,葛均波,梁春,罗育坤,黄东,王克强,陈灏珠.糖基化终产物对人单核细胞源树突状细胞清道夫受体A表达的影响及其机制的研究[J].中华心血管病杂志,2004,32(10):888-892. 被引量:9
  • 2Ross IL Atherosclerosis--an inflammatory disease. N Engl J Med,1999,340:115-126.
  • 3Hansson GK, Libby P, Schonbeck U, et al. Innate and adaptive immunity in the pathogenesis of athemsclerosis. Circ Res, 2002,91 :281-291.
  • 4Bobryshev YV, Lord RS. Mapping of vascular dendritic cells in atherescleretic arteries suggests their involvement in local immune-inflammatory reactions. Cardiovasc Res, 1998,37:799-810.
  • 5Ge J, Jia Q, Liang C, et al. Advanced glycosylation end products might promote atherosclerosis through inducing the immune maturation of dendritic cells. Arterioscler Thromb Vasc Biol, 2005,25:2157-2163.
  • 6Laakso M. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes, 1999,48:937-942.
  • 7Wick G, Perschinka H, Millonig G. Atherescleresis as an autoimmune disease: an update. Trends Immunol, 2001,22: 665-669.
  • 8Aicher A, Heeschen C, Mohaupt M, et al. Nicotine strongly activates dendritic cell-mediated adaptive immunity : potential role for progression of atherosclerotic lesions. Circulation, 2003, 107: 604-611.
  • 9Alderman CJ, Bunyard PR, Chain BM, et al. Effects of oxidised low density lipoprotein on dendritic cells: a possible immunoregulatory component of the atherogenic micro-environment? Cardiovasc Res,2002,55:806-819.
  • 10Michael B. Biochemistry and molecular cell biology of diabetic complication. Nature, 2001, 414:813-817.

共引文献17

同被引文献26

  • 1秦玲,张淑琴,张家颖.阿托伐他汀对家兔动脉粥样硬化血管细胞粘附分子-1基因表达的影响[J].中风与神经疾病杂志,2005,22(4):300-302. 被引量:5
  • 2Skal6n K, Gustafsson M, Rydberg EK, et al. Subendothelial re- tention of atherogenic lipoproteins in early atherosclerosis[J]. Na- ture, 2002,417 (6890) : 750-754.
  • 3Hegland O, Dickstein K, Larsen JP. Effect of simvastatin in pre- venting progression of carotid artery stenosis [J]. Am J Cardiol, 2001,87 (5) :643-645.
  • 4Serruys PW, Garcfa-Garc a HM, Buszman P, et al. Effects of the direct lipoprotein-associated phospholipase A (2) inhibitor dara- pladib on human coronary atherosclerotic plaque[J]. Circulation, 2008,118(11) : 1172- 1182.
  • 5Tardif JC, L' allier PL, Ibrahim R, et al. Treatment with 5-1ipoxy- genase inhibitor VIA-2291 (Atreleuton) in patients with recent acute coronary syndrome [J]. Circ Cardiovasc Imaging, 2010,3 (3) : 298-307.
  • 6kkonen HM, Vahakangas E, Marr RA, et al. Long-term lowering of plasma cholesterol levels in LDL-receptor-deficient WHHL rabbits by gene therapy[J]. Mol Ther, 2004,9 (4) : 548 -556.
  • 7Oka K,Pastore L, Kim IH, et al. Long-term stable correction of low-density lipoprotein receptor-deficient mice with a helper-de- pendent adenoviral vector expressing the very low-density lipo- protein receptor[J]. Circulation,2001,103(9) : 1274-1281.
  • 8Brousseau ME, Kauffman RD, Herderick EE, et al. LCAT modu- lates atherogenic plasma lipoproteins and the extent of athero- sclerosis only in the presence of normal LDL receptors in trans- genic rabbits [J]. Arterioscler Thromb Vasc Biol, 2000,20 (2) : 450-458.
  • 9Li B,Zhang J, Li Z, et al. Adeno-associated virus serotype 2 me- diated transduction and coexpression of the human apoAI and SR-BI gene in HeopG2 cells[J]. Mol Biol Rep,2012,39 (1):25- 32.
  • 10Lippi G, Favaloro EJ. Antisense therapy in the treatment of hy- percholesterolemia[J]. Eur J Intern Med,2011,22 (6) :541-546.

引证文献1

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部